title: The national kidney transplant program in Norway still results in unchanged waiting lists.
abstract: 1. Of 2,670 patients starting renal replacement therapy for end-stage renal disease in Norway from 1989-1997, 76% were candidates for transplantation. The annual need for transplantations increased from 47 to 64 grafts PMP as the number of elderly patients increased. The national waiting list has remained almost stable during the period from 1989-1997 at levels of 25-30 PMP, but the dialysis population has increased from 57-105 PMP. 2. A total of 1,681 transplants was performed at an annual rate varying between 38 and 46 grafts PMP. The grafts were procured from LDs in 41% and CDs in 59% of cases. Totally 69% of all patients in need were transplanted and 54% of all patients requiring replacement therapy for end-stage renal disease received a transplant. 3. Graft survival rates in recipients of first LD grafts (n = 641) were 91% and 77% at one and 5 years, respectively. One-year graft survival was 97% in HLA-identical grafts (n = 71), 92% in haploidentical grafts (n = 419), 88% in 2 haplotype-mismatched related grafts (n = 43), and 87% in spousal donor grafts (n = 108). 4. Graft survival rates in recipients of first CD grafts (n = 801) were 84% and 65% at one and 5 years, respectively. The rates were 86% and 74% in younger (n = 557) versus 78% and 46% in older (> 65 years) (n = 244) patients. Death with a functioning graft caused approximately 45% and 75% of all graft losses in younger and older patients, respectively. Cardiovascular disease was the major cause of death. 5. A significant beneficial effect of HLA-DR matching was observed in CD grafts performed after 1989, in particular in patients older than age 65.
authors.affiliation: Rikshospitalet, University of Oslo, Norway.
authors.forename: O H
authors.initials: OH
authors.lastname: Bentdal
authors.forename: T
authors.initials: T
authors.lastname: Leivestad
authors.forename: P
authors.initials: P
authors.lastname: Fauchald
authors.forename: D
authors.initials: D
authors.lastname: Albrechtsen
authors.forename: P
authors.initials: P
authors.lastname: Pfeffer
authors.forename: B
authors.initials: B
authors.lastname: Lien
authors.forename: A
authors.initials: A
authors.lastname: Foss
authors.forename: O
authors.initials: O
authors.lastname: Oyen
authors.forename: A
authors.initials: A
authors.lastname: Hartmann
authors.forename: K
authors.initials: K
authors.lastname: Nordal
authors.forename: G
authors.initials: G
authors.lastname: Sødal
authors.forename: A
authors.initials: A
authors.lastname: Flatmark
authors.forename: E
authors.initials: E
authors.lastname: Thorsby
authors.forename: I B
authors.initials: IB
authors.lastname: Brekke
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007223:Infant; D007676:Kidney Failure, Chronic / Q000628:therapy; D016030:Kidney Transplantation / Q000401:mortality / Q000502:physiology / Q000706:statistics & numerical data*; D019520:Living Donors / Q000706:statistics & numerical data*; D008875:Middle Aged; D009664:Norway; D012042:Registries; D017582:Renal Replacement Therapy; D012086:Reoperation; D012189:Retrospective Studies; D015996:Survival Rate; D014019:Tissue Donors / Q000600:supply & distribution*; D009927:Tissue and Organ Procurement / Q000458:organization & administration* / Q000706:statistics & numerical data; D014850:Waiting Lists